Page last updated: 2024-12-04

nicotine 1-n-oxide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

nicotine 1-N-oxide: RN given refers to unspecified stereoisomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

nicotine N(1')-oxide : A tertiary amine oxide resulting from the oxidation of the pyrrolidine nitrogen of nicotine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID409
CHEBI ID30734
SCHEMBL ID1538468
MeSH IDM0082307

Synonyms (25)

Synonym
pyridine, 3-(1-methyl-2-pyrrolidinyl)-, n-oxide, (2s)-
63551-14-4
3-(1-methyl-1-oxidopyrrolidin-2-yl)pyridine
1-methyl-2-(3-pyridyl)pyrrolidine 1-oxide
nicotine n(1')-oxide
1-methyl-2-(3-pyridyl)-2,3,4,5-tetrahydropyrrol-1-olate
CHEBI:30734
nicotine 1-n-oxide
3-(1-methyl-1-oxido-2-pyrrolidinyl)pyridine
3-(1-methyl-1-oxidopyrrolidin-1-ium-2-yl)pyridine
nicotine 1'-oxide
3-(1-methyl-2-pyrrolidinyl)pyridine, n-oxide
nicotine-1'-oxide
(-)-nicotine 1'-oxide
(-)-nicotine 1'-n-oxide
SCHEMBL1538468
1-methyl-2-(pyridin-3-yl)pyrrolidin-1-ium-1-olate
n-oxide-(1-methyl-2-pyrrolidinyl)pyridine
n-oxide 3-(1-methyl-2-pyrrolidinyl)pyridine
(2s)-n-oxide 3-(1-methyl-2-pyrrolidinyl)-pyridine
1'-oxide nicotine
oxynicotin
Q27113968
AKOS034834174
DTXSID601262724

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" However, age-related pharmacokinetic differences may confound the interpretation of these findings."( Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.
Craig, EL; Cui, JZ; Miksys, S; Novalen, M; Tyndale, RF; Zhao, B, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" The pattern of metabolites after iv dosing suggests that there is systemic reduction of NNO, although the magnitude of that reduction is small, with less than 3% reduced to nicotine."( Disposition kinetics and metabolism of nicotine-1'-N-oxide in rabbits.
Benowitz, NL; Duan, MJ; Jacob, P; Savanapridi, C; Yu, L,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
pyrrolidine N-oxidesAny member of the class of pyrrolidines that are substituted by an organyl group at position 1 and in which the amino group of the pyrrolidine ring has been oxidised to give the corresponding N-oxide.
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Nicotine Action Pathway3832
Nicotine Metabolism Pathway923
Nicotine metabolism011
Nicotine metabolism in liver cells011

Research

Studies (25)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (48.00)18.7374
1990's6 (24.00)18.2507
2000's3 (12.00)29.6817
2010's3 (12.00)24.3611
2020's1 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.23%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (96.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]